The inhibition of isoforms of nitric oxide synthase: non-cardiovascular aspects

The very recent patent literature covering the inhibition of the various isoforms of nitric oxide synthase (NOS) is reviewed. Claims are generally for therapy of various inflammatory states, for therapy for a number of central nervous system (CNS) indications, and cancer therapy. Patent applications covering other aspects of control of nitric oxide (NO) concentrations in mammals are very briefly reviewed, although they fall outside of the scope of NOS per se. This includes agents that release NO in situ. Same applications covering the NOS genome are also described.